Determining efficacy of cancer chemopreventive agents using a cell-free system concomitant with DNA adduction

W A Smith1, R C Gupta

  • 1Graduate Center for Toxicology, Room 354, Health Sciences Research Building, University of Kentucky Medical Center, Lexington, KY 40536-0305, USA.

Mutation Research
|March 20, 1999
PubMed

Insights

Identifying effective cancer chemopreventive agents requires short-term screening. This study classified 26 agents based on their impact on benzo[a]pyrene (BP)-DNA adducts, identifying promising candidates for further research.

Area of Science:

  • Chemoprevention research
  • Molecular toxicology
  • Biochemical screening

Background:

  • The vast number of potential cancer chemopreventive agents necessitates efficient screening methods.
  • Traditional long-term animal bioassays and clinical trials are economically and practically infeasible for initial testing.
  • A pilot study demonstrated the utility of a microsome-mediated test system with DNA adduction for rapid efficacy assessment.

Purpose of the Study:

  • To extend previous findings by evaluating 26 additional agents for cancer chemopreventive potential.
  • To investigate the effects of these agents on microsome-mediated benzo[a]pyrene (BP)-DNA adduction.
  • To categorize agents based on their differential effects on specific BP-DNA adducts.

Main Methods:

  • Utilized a microsome-mediated test system to assess the impact of 26 agents on benzo[a]pyrene (BP)-DNA adduction.
  • Analyzed the differential effects of agents on two major BP-DNA adducts: BP-7,8-diol-9,10-epoxide (BPDE)-deoxyguanosine (dG) and 9-OH-BP-dG.
  • Categorized agents into five classes based on their inhibitory or enhancing effects on these specific adducts.

Main Results:

  • Three agents (ellagic acid, genistein, oltipraz) strongly inhibited both BP-DNA adducts (Class I, 65-95% reduction).
  • Six agents moderately inhibited both adducts (Class II, 25-64% reduction).
  • Other agents showed selective inhibition, were ineffective, or enhanced adduct formation (Class III-V).

Conclusions:

  • Class I and Class II agents, demonstrating significant inhibition of BP-DNA adducts, are promising candidates for further cancer chemoprevention studies.
  • The study highlights the importance of analyzing individual DNA adducts rather than total DNA binding.
  • The microsome-mediated DNA adduction assay serves as a valuable short-term screening tool for chemopreventive agents.